+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Pharmaceutical Isolator Market - Growth, Trends, Covid-19 Impact, and Forecasts (2022 - 2027)

  • PDF Icon

    Report

  • 120 Pages
  • August 2022
  • Region: Global
  • Mordor Intelligence
  • ID: 5616769
The Pharmaceutical Isolator Market is projected to register a CAGR of 10% during the forecast period (2022-2027).

The coronavirus outbreak increased the demand for pharmaceuticals, resulting in the growth of the pharmaceutical isolator market during the pandemic. For instance, in 2020, the article titled' short and long term impact impacts of COVID-19 on the pharmaceutical sector' mentioned that COVID-19 increased the demand for prescription medicines, vaccines, and medical devices. Such studies prove the increase in demand for pharmaceuticals, increasing the employment of pharmaceutical isolators in the pharmaceutical industry.

Major factors such as greater sterility assurance of the pharmaceutical isolators are expected to drive the market's growth during the forecast period. The immense sterility assurance of pharmaceutical isolators results in expanding the market demand. The preparations of the pharmaceutical manufacturing process include the inclusion of Active pharmaceutical ingredients with high potency, which require extreme caution and sterile environments assuring the contents from contamination. The pharmaceutical isolator satisfies the needs of the sterile environment n the manufactured process and delivers the desired finished product. The increasing innovative launches by the market players to meet the growing demand of the end users is expected to boost the v growth of the market. For instance, in January 2019, TEMA SINERGE S.P.A set up the active Bio-deca pass with the chamber (AB-PTC) with an integrated vaporized hydrogen peroxide bio-contamination system for AJ vaccine production. Therefore, the above factors are expected to drive the market's growth.

Key Market Trends


The Pharmaceutical and Biotechnology companies are


The sudden outbreak of COVID-19 had increased the demand for biologics to treat the infected people and provide vaccinations. The pharmaceutical and biotechnology segments are expected to hold the major share in the forecast period owing to the novel drug development and protein pharmaceutical synthesis using recombinant DNA technology.

Key factors such as increasing expenditure in the research and development by the pharmaceuticals and biotechnology industries to develop protein-based therapy are expected to significantly impact the market's growth. According to the data published by Organisation for Economic Co-Operation and Development (OECD) in 2020, the pharmaceutical industry spent nearly USD 101 Billion on Research and Development in the OECD countries. Also, the same source reported that global R&D spending by the largest publicly- traded companies grew 13.7% annually. Therefore, the increasing expenditure on research and development by the pharmaceutical and biotechnology industries to develop their product pipeline is expected to boost the growth of the expression vectors market. Hence, the pharmaceutical and biotechnology industries are expected to hold a significant share in the market during the forecast period.



North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period


The increase in the adoption of highly advanced techniques and systems in genomics and proteomics, novel drug discovery, and development is expected to boost the market's growth in the North American region. Also, the increasing funding from government organizations for research and development activities in the United States is a major contributing factor to the market growth in this region. According to the data published by the National Center for Biotechnology Information (NCBI), Biotechnology funding by the National Institute of Health (NIH) was around 7.77 Billion USD during the fiscal year 2020. Also, the data published by the Federation of American scientists reported that federal funding for research and development grew 5.9% in 2020 compared to 2019, which was 138.9 billion USD. The Nation’s 42 federally funded research and development centers spend around 23.5 Billion USD on research and development in the fiscal year 2020. Additionally, the presence of major market players in this region is also a major factor in the growth of the market in this region.



Competitive Landscape


The Pharmaceutical isolators market is fragmented and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are Getimge AB, Chiyoda Corporation, Azbil Corporation, Germfree MBRAUN, Wabash National Corporation, NuAire, ITECO s.r.l, COMECER s.p.s, Hosokawa, Hecht Technologie GmbH, TEMA SINERGIE S.p.A, Bioquell Inc and Others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support


This product will be delivered within 2 business days.

Table of Contents

1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Need of Sterility and Assurance of Pharmaceutical Isolator
4.2.2 Low Operational Cost of Pharmaceutical Isolators
4.3 Market Restraints
4.3.1 Availability of Alternatives
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Type
5.1.1 Closed Isolator Systems
5.1.2 Open Isolator Systems
5.2 By Application
5.2.1 Aseptic Isolators
5.2.2 Containment Isolators
5.2.3 Others
5.3 By End user
5.3.1 Pharmaceutical and Biotechnology Companies
5.3.2 Research Laboratories
5.3.3 Others
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle-East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle-East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Getimge AB
6.1.2 Chiyoda Corporation
6.1.3 Azbil Corporation
6.1.4 Germfree MBRAUN
6.1.5 Wabash National Corporation
6.1.6 NuAire
6.1.7 ITECO s.r.l
6.1.8 COMECER s.p.A
6.1.9 Hosokawa
6.1.10 Hecht Technologie GmbH
6.1.11 TEMA SINERGIE S.p.A
6.1.12 Bioquell Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Getimge AB
  • Chiyoda Corporation
  • Azbil Corporation
  • Germfree MBRAUN
  • Wabash National Corporation
  • NuAire
  • ITECO s.r.l
  • COMECER s.p.A
  • Hosokawa
  • Hecht Technologie GmbH
  • TEMA SINERGIE S.p.A
  • Bioquell Inc.

Methodology

Loading
LOADING...